Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies

Page 1 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study of huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ CancersNot yet recruitingNCT07891468Phase 1
• Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Not yet recruitingNCT07887061Phase 2
• RPM Signals in Outpatient CAR T TherapyNot yet recruitingNCT07882732
• Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLNot yet recruitingNCT07847957Phase 1/2
• Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKINot yet recruitingNCT07819214Phase 2
• Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 TrialNot yet recruitingNCT07812246Phase 2
• Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 InhibitorNot yet recruitingNCT07796373Phase 2
• Ibrutinib Plus Venetoclax Long-Term Outcomes in CLLRecruitingNCT07774390
• Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruitingNCT07763054
• Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination TherapiesNot yet recruitingNCT07759661
• A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Not yet recruitingNCT07753369Phase 3
• Targeting IRAK4 in Chronic Lymphocytic LeukemiaNot yet recruitingNCT07741695
• Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Not yet recruitingNCT07739459Phase 2
• Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 AlterationsNot yet recruitingNCT07738887Phase 2
• Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT07734038Phase 2
• Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor TherapyNot yet recruitingNCT07711327
• A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)Not yet recruitingNCT07709000Phase 2
• Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic LeukemiaNot yet recruitingNCT07690891Phase 2
• Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic LeukemiaRecruitingNCT07685717Phase 2
• Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0Not yet recruitingNCT07682415Phase 2
• BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic MalignanciesNot yet recruitingNCT07679919Phase 1
• A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic LeukemiaNot yet recruitingNCT07674810Phase 2
• Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesRecruitingNCT07648264Phase 3
• Impact of Targeted Therapy on Cancer-Related Cognitive ImpairmentRecruitingNCT07638007
• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingNCT07609862Phase 1/2
• A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT07609823Phase 2
• A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic LeukemiaRecruitingNCT07602088
• Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK InhibitorsNot yet recruitingNCT07592481Not applicable
• A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaRecruitingNCT07582432Phase 3
• Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNot yet recruitingNCT07582159Phase 2
• Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT07557056Phase 2
• Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK InhibitorsNot yet recruitingNCT07526597Phase 2
• Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesRecruitingNCT07520006Phase 1/2
• Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLRecruitingNCT07516093Phase 3
• A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)RecruitingNCT07508995Phase 2
• A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell MalignanciesNot yet recruitingNCT07476378Not applicable
• Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsEnrolling by invitationNCT07474051
• variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia PathwayNot yet recruitingNCT07463976
• Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibRecruitingNCT07428707Early Phase 1
• Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingNCT07426484Phase 4
• This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including RNot yet recruitingNCT07412405Not applicable
• ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingNCT07342478Phase 3
• Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLRecruitingNCT07321652Phase 3
• LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTIONRecruitingNCT07313982
• Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in BelarusRecruitingNCT07288515
• Precision Physical Exercise for Personalized Onco-Hematology.Not yet recruitingNCT07286539Not applicable
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingNCT07277231Phase 3
• A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesRecruitingNCT07271667Phase 2
• Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 1
• A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)RecruitingNCT07221500Phase 2
• Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity TrialRecruitingNCT07218510Phase 2
• A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT07218341Phase 4
• A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic AnemiaRecruitingNCT07205315Early Phase 1
• Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT07194980Phase 2
• Watch and Wait or Worry and Wait in Indolent LymphomaEnrolling by invitationNCT07173790
• CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasEnrolling by invitationNCT07168486Phase 1
• Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia PatientsNot yet recruitingNCT07162532
• Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma PatientNot yet recruitingNCT07157579
• A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)RecruitingNCT07154264Phase 2
• HPC Offered for PRESERVE ExpansionRecruitingNCT07145411
• A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)RecruitingNCT07139873Phase 3
• Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic LeukemiaNot yet recruitingNCT07113132
• Study of Epcoritamab as a Consolidation Therapy in CLL/SLLRecruitingNCT07108998Phase 2
• Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic LeukemiaRecruitingNCT07099443
• A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive InductionNot yet recruitingNCT07082452Phase 3
• Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaRecruitingNCT07061951Phase 2
• Mosunetuzumab for CLL MRD ClearanceRecruitingNCT07052695Phase 1/2
• Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic LymphomaRecruitingNCT07030400
• MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingNCT07024706Phase 2
• A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell TransplantRecruitingNCT07020533Phase 1
• Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLRecruitingNCT07014917Phase 2
• Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center StudyNot yet recruitingNCT07003464Phase 2
• Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT06980116Phase 1
• A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLLNot yet recruitingNCT06979076Phase 1/2
• LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of ThisRecruitingNCT06978088Phase 2
• A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT06973187Phase 3
• Evaluation of Skin Tests in Biotherapy AllergiesRecruitingNCT06971848Not applicable
• Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingNCT06967610Phase 2
• Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyRecruitingNCT06958705Phase 2
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingNCT06943872Phase 3
• A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin LymphomaRecruitingNCT06876662Phase 4
• A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibRecruitingNCT06876649Phase 4
• Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeRecruitingNCT06863402Phase 2
• Time Restricted Eating in Haematological MalignanciesNot yet recruitingNCT06862323Phase 2
• Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramRecruitingNCT06860880Not applicable
• Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06859008Phase 1
• Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLRecruitingNCT06849713Phase 2
• A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsRecruitingNCT06846671Phase 3
• Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaRecruitingNCT06839053Phase 2
• CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and LymphomaRecruitingNCT06834529Phase 1/2
• Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID ProjectRecruitingNCT06821880
• Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With ZanubrutinibRecruitingNCT06812715Phase 2
• A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSGRecruitingNCT06792994
• A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788639
• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
• Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T TreatmentRecruitingNCT06784167
• Real-world Study of AcalabrutinibEnrolling by invitationNCT06767891
• Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.RecruitingNCT06762431Phase 1/2
• Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT06757647Phase 2
• Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1

← Leukemia, Lymphocytic, Chronic, B-Cell overview